Dr. Jorge Luis Jo Kamimoto, MD

Dr. Jo Kamimoto practices at Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr) in Philadelphia, Pennsylvania.

Dr. Jo Kamimoto's NPI, 1063856193, was assigned on April 19, 2013. Dr. Jo Kamimoto holds Pennsylvania license MD464402.

Dr. Jo Kamimoto's primary practice is Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr), at 3400 Spruce Street, White Bldg 1st Flr, Philadelphia, PA 19104.

Dr. Jo Kamimoto's primary practice is Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr) in Philadelphia, Pennsylvania. Dr. Jo Kamimoto is also affiliated with Hospital of the University of Pennsylvania. The medical group on file is Penn Medicine Lancaster General Health. Dr. Jo Kamimoto's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jo Kamimoto practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Jo Kamimoto's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Jo Kamimoto is licensed in Pennsylvania.

CMS data shows 471 Medicare services from Dr. Jo Kamimoto across 5 procedure codes in 2024, for 266 Medicare patients. Medicare paid $37,880 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 266 Medicare patients who saw Dr. Jo Kamimoto in 2024. The largest group is 65 to 74, with 128 patients. 75% of them have diabetes, and 75% have high blood pressure. 28% are also on Medicaid. Their average risk score is 3.87, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jo Kamimoto's median patient age at 59, with 43% women.

In 2024, Dr. Jo Kamimoto wrote 513 Medicare Part D claims for 92 patients. 18% of them were for generic drugs. CMS names the drug for 360 of them, across 14 drugs with 11 or more claims each, at $132,040 in total drug cost. In 2023, CMS named 251 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Jo Kamimoto for performance year 2024, reported as part of a group. Dr. Jo Kamimoto accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Jo Kamimoto as offering telehealth.

Dmand AI links 4 papers to Dr. Jo Kamimoto, published from 2016 to 2024. Dr. Jo Kamimoto's most frequent co-authors are Bart Barlogie, MD, Faith E. Davies, MD and Monica Liliana Grazziutti, MD.

CMS Open Payments shows 8 general payments to Dr. Jo Kamimoto from 2 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 51% of the total. Astellas Pharma US Inc paid the most, $533.